Eli Lilly Launches Website for Community Oncologists

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 2
Volume 10
Issue 2

INDIANAPOLIS-Eli Lilly and Company has launched a new website for community medical oncologists and their staffs. The site, located at www.lillydirect.com, is designed to save oncology health care professionals time by streamlining many of their business-related responsibilities.

INDIANAPOLIS—Eli Lilly and Company has launched a new website for community medical oncologists and their staffs. The site, located at www.lillydirect.com, is designed to save oncology health care professionals time by streamlining many of their business-related responsibilities.

For example, using the new website, physicians can access several major wholesale distributors of oncology products at one time to place orders for chemotherapeutic agents.

Other features of the website include reimbursement assistance, patient messaging, medical information on Lilly oncology products, and links to information on Lilly and non-Lilly oncology clinical trials, publications, scientific meetings, and cooperative groups and associations.

Articles in this issue
Activated T Cells Can Alter Behavior of Leukemic B Cells
Response Continues for at Least 8 Months with Ibritumomab Tiuxetan
Chemotherapy Without Methotrexate Achieves Superb Results in Children With NHL
Iodine I 131 Tositumomab Induces Response in 70% of Patients Progressing After Rituximab
Synthetic Anthracycline Produces High Response Rates in SCLC
Ibritumomab Tiuxetan Produces 73% Response Rate in B-cell NHL
Rituximab Produces Clinical Responses in Even Steroid-Refractory Idiopathic Thrombocytopenic Purpura
G-CSF Might Prolong Rituximab Responses in NHL
Use of CAD Increases the Early Detection of Breast Cancer by 20%
Rituximab Plus Fludarabine May Be Good Alternative to Rituximab Plus CHOP
Student Cigarette Smoking Falls Significantly
Injectable COX-2 Inhibitor Effective in Postsurgery Pain
Patients’ Exercise Needs May Differ After Cancer Therapy
HAART Improves Survival in HIV-Positive NHL Patients
Liposomal Tretinoin Produces Impressive Responses in Refractory B-cell and T-cell Lymphomas
Recent Videos
Genetic consultation and next-generation sequencing can also complement treatment strategies for patients with pancreatic cancer.
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Immunotherapy options like CAR T-cell therapy and antigen-presenting cell-directed agents are currently being evaluated in the pancreatic cancer field.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
2 experts are featured in this video
2 experts are featured in this video
2 experts are featured in this video
4 KOLs are featured in this series.
Related Content
An advanced computation linguistics model that can detect pancreatic cysts can help patients prevent pancreatic tumors from forming.

Adapting a Computation Linguistics Model to Surveil for Pancreatic Cancer

Russell C. Langan, MD
November 24th 2024
Article

An advanced computation linguistics model that can detect pancreatic cysts can help patients prevent pancreatic tumors from forming.

A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.

Collaboration Fosters Treatment Advancements for Young Lymphoma Populations

Andrew M. Evens, DO, MS
November 18th 2024
Podcast

A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.

Vusolimogene oderparepvec in combination with nivolumab has received breakthrough therapy designation from the FDA in advanced melanoma.

FDA Assigns BTD and Receives BLA for RP1 Combo in Advanced Melanoma

Tim Cortese
November 22nd 2024
Article

Vusolimogene oderparepvec in combination with nivolumab has received breakthrough therapy designation from the FDA in advanced melanoma.

Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.

Educating Patients and Clinicians on End-of-Life Care and Discussions

Kelley A. Rone, DNP, RN, AGNP-c
November 11th 2024
Podcast

Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.

Darolutamide with androgen deprivation therapy has shown promising efficacy and safety results for patients with hormone-sensitive prostate cancer.

FDA Accepts sNDA for Darolutamide/ADT in Hormone-Sensitive Prostate Cancer

Tim Cortese
November 21st 2024
Article

Darolutamide with androgen deprivation therapy has shown promising efficacy and safety results for patients with hormone-sensitive prostate cancer.

Multiple Myeloma Experts Face Off on Sequencing Therapy Options

Multiple Myeloma Experts Face Off on Sequencing Therapy Options

ONCOLOGY Staff
November 21st 2024
Article

Experts in multiple myeloma gathered to debate current treatment options in the space during a recent Face Off.